Celldex Therapeutics announced that Sam Martin, the Senior Vice President and Chief Financial Officer, intends to retire in 2027 and will remain in his role through March 2027 to ensure a smooth transition as the company searches for a new CFO. Martin has been with Celldex since 2009 and has served as CFO since 2017, and the firm has started a formal search to fill the position. The company’s leadership emphasized gratitude for Martin’s contributions and expressed optimism about Celldex’s path as it advances a robust immunology pipeline, including two Phase 3 barzolvolimab trials expected later this year. An insider activity note from one source highlights about $1.32 million in stock sells over the past year, underscoring market attention around the leadership change. Celldex positions itself as a late-stage immunology company pursuing new antibody-based therapies, with ongoing efforts to scale its commercial capabilities alongside R&D milestones. The firm reaffirmed its commitment to a careful transition to maintain stability in financial operations during a period of leadership change.